[A24-25] Enalapril (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 03.06.2024
Project no.:
A24-25
Commission:
Commission awarded on 01.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Indication:
Children and adolescents with heart failure.
Result of dossier assessment:
- Children and adolescents aged 1 to 17 years with heart failure: added benefit not proven
- Children aged < 1 year with heart failure: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-25_en